alexa Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
Microbiology

Microbiology

Journal of Antivirals & Antiretrovirals

Author(s): Jacobson IM

Abstract Share this page

The combination of peginterferon and ribavirin is considered a standard of therapy for patients chronically infected with either genotype 2 or 3 hepatitis C virus (HCV). This regimen is associated with high rates of sustained virologic response (SVR) in both untreated and previously treated patients (70%-85% and 55%-60% response rates in each group, respectively).1-4 However, there is currently a major gap in the field of hepatitis treatment of patients with HCV genotype 2 or 3 who are either unable to be treated with peginterferon or who previously failed to have a response to peginterferon. The number of patients affected by this is not insignificant; one report estimated that this patient group comprises the majority of HCV-infected patients.4 Thus, treatment alternatives are needed for chronically HCV-infected patients who are either unable to be treated with peginterferon or who previously failed to have a response to peginterferon. One potential treatment is the oral nucleotide analogue sofosbuvir. In vitro studies show that sofosbuvir is active across all HCV genotypes.5 A phase 2 trial in patients with chronic HCV infection (either genotype 2 or 3) found that treatment with sofosbuvir plus ribavirin resulted in a SVR in 100% (10 of 10) of previously untreated patients and 68% (17 of 25) of previously treated patients.6,7 Based on this, 2 phase 3 trials were designed to evaluate sofosbuvir plus ribavirin specifically in genotype 2 or 3 HCV-infected patients in whom either peginterferon therapy was not an option or who had previously failed to respond to peginterferon.8

  • To read the full article Visit
  • DOI:
  • Open Access
This article was published in Gastroenterol Hepatol and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords